ReviewReviews in cardiovascular medicine2026
Myocardial Ischemia-Reperfusion Injury: Molecular Mechanisms and Innovative Therapeutic Strategies.
Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial ischemia-reperfusion injury (MIRI) is a critical pathological paradox following revascularization in acute myocardial infarction, yet effective clinical interventions remain limited. MIRI involves a complex, interlinked hierarchy of programmed cell death modalities, including ferroptosis, pyroptosis, and cuproptosis, which form a network mediated by the stimulator of interferon genes-glutathione peroxidase 4 (STING-GPX4), NOD-like receptor pyrin domain containing 3-gasdermin D (NLRP3-GSDMD), and sirtuin 3-ATPase copper transporting alpha (SIRT3-ATP7A) axes. The dynamic evolution of the immune microenvironment, mitochondrial dysfunction, and non-coding RNA regulatory networks further compound this. Emerging strategies, including bionanotechnology-enabled targeted delivery, intelligent responsive biomaterials, drug repurposing, genome editing, and precise ion channel modulation, demonstrate significant therapeutic potential. Despite bottlenecks in clinical translation related to delivery efficiency, patient heterogeneity, and efficacy evaluation, multidisciplinary integration and technological innovations are propelling a paradigm shift in MIRI treatment from revascularization alone to comprehensive myocardial protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.